ghp July 2015 | 9 Precyse Acquisition Boosts Pamplona’s Portfolio Precyse, a leader in Health Information Management services, education and technology, is being pur- chased from Altaris Capital Partners and NewSpring Capital for an undisclosed sum. The new acquisition will be an impressive addi- tion to Pamplona’s expanding health investment portfolio which also encompasses: Spreemo, a firm that is bringing cost transparency and quality metrics to the workers compensation specialty benefits management industry with an initial focus on radiology; Intralign, which helps hospital and surgeons achieve a rep-less, optimized surgical episode by combining assessment with clinical support and operational tools; Magnacare, a leading healthcare administrative services company focused on self-insured employers and workers comp plans in the New York and New Jersey regions; and Privia Health, a physician practice management and population health technology company. The firm previously owned Alvogen, a high growth generic drugs company, but sold the majority of their stake in the firm in June to a consortium of investors. Dr. Jeremy Gelber, a Pamplona Capital Management partner who is leading the investment, made it clear that the new acquisition would benefit both of the firms involved as well as their customers. ‘Precyse has established itself as a leader in Health Information Management with the ability to fully out- source HIM departments, provide services or tech- nology on an as-needed basis, and supply education tools to help hospitals achieve better outcomes. We and Precyse have a shared vision in expanding the business beyond the company’s traditional offerings into other areas that positively impact providers’ clini- cal and financial outcomes, both in Health Informa- tion Management and beyond.’ Precyse is certainly a shrewd investment for the firm and also represents a large section of the American healthcare market, delivering a robust combina- tion of experienced, highly trained people, premier technology solutions, and industry-leading education which they target at all clinical and financial aspects of Health Information Management. Collectively, this equips healthcare organizations to achieve en- hanced, sustainable operational performance. The CEO of Precyse, Chris Powell, was keen to es- tablish that being acquired by Pamplona would allow the firm scope to grow and increase their influence in the industry. ‘We are delighted to be partnering with Pamplona Capital at this exciting time in Precyse’s evolution. Precyse has a wide range of services, education and technology solutions that enable us to help health- care organizations thrive. Pamplona will help us meet our growth objectives as we continue to build on our successful solutions today and expand our of- ferings in the future to help healthcare organizations reach new levels of operational success.’ Pamplona Capital Management has added Precyse, the health- care management specialists, to their growing collection of healthcare firms making them a key player in the healthcare industry. Global Drug Delivery Tech Market Will Offer Investors Relief A new report by visiongain predicts that the world market for drug delivery technologies will reach $159.3 billion in 2015. The forecast appears in ‘Drug Delivery Technol- ogies Market Forecast 2015-2025: Prospects for Leading Companies’. The global market for drug delivery technolo- gies has experienced strong growth in recent years, and visiongain expects this growth to continue over the forecast period used in the report, which extends between 2015 and 2025. The market will be boosted by the increasing number of biological drugs on the market as they are inherently difficult to administer by traditional drug delivery methods. Furthermore, the use of vaccines with innovative delivery platforms such as nasal sprays and transdermal patches is set to expand significantly over the next decade. Transdermal and injectable drug delivery tech- nologies will witness the highest growth over the forecast period, obtaining market shares from oral drug delivery technologies. A number of manu- facturers are increasingly shifting their focus to biological drugs, which normally require injection. A key example of this is Eli Lilly, a big contender in the global pharmaceuticals industry, is strength- ening its pipeline of biological drugs and a new drug delivery innovation centre will be built. The report states that developed countries in North America and Europe are currently dom- inating the drug delivery technologies market, owing to their establishment in the pharmaceu- ticals sector and the fact that they are financial- ly stable. Emerging markets such as China and India continue to grow rapidly, obtaining market share from western countries. The market for drug delivery technologies has experienced strong growth in recent years, and the report expects this growth to continue over the forecast period of 2015 to 2025. The mar- ket will be boosted by the increasing number of biological drugs on the market as they are inherently difficult to administer by traditional drug delivery methods. Additionally, the use of vaccines with innovative delivery platforms such as nasal sprays and transdermal patches is set to expand significantly over the next decade as customers reject more painful, traditional methods of taking drugs in fa- vour of more simpler, more modern techniques. Drug manufacturers in the drug delivery sector are continuously striving to develop drug deliv- ery options that provide patient-friendly dosage forms. Consequently, drug delivery technol- ogy will continue to play an important role in developing next generation drugs, particularly in biologics and vaccines, as patients continue to require easier means of taking medicines and companies continue to develop their technology.